Andere talen PMV Pharmaceuticals, Inc.

Aandelen

PMVP

US69353Y1038

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,8 ^USD	+1,69%		-0,28%	-41,94%

12/04	PMV PHARMACEUTICALS, INC. : Jefferies & Co. bevestigt koopadvies	ZM
27/03	PMV Pharmaceuticals, Inc. Kondigt aan dat de eerste patiënt gedoseerd is in de wereldwijde tumoragnostische Fase 2 PYNNACLE studie voor Rezatapopt in TP53 Y220c-positieve vaste tumoren	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	27/03
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	27/03
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer	18/03
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	18/03
North American Morning Briefing : Stock Futures -2-	06/03
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	29/02
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference	26/02
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway	18/01
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%	18/01
MORNING BRIEFING - USA/Asien	08/01
PMV Pharmaceuticals Names Michael Carulli as CFO; Phase 2 Trial of Tumor Treatment on Track	05/01
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development	05/01
PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	05/01
PMV Pharmaceuticals, Inc. Announces Executive Changes	05/01
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from NASDAQ Biotechnology Index	15/12
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights	09/11
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
PMV Pharmaceuticals Says Updated Trial Data Show Cancer Therapy Induces Anti-Tumor Activity; Shares Fall	12-10-23
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation	12-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen PMV Pharmaceuticals, Inc.

Aandelen

PMVP

US69353Y1038

Andere talen

Filters